{"id":"cip-isotretinoin","safety":{"commonSideEffects":[{"rate":"5-25","effect":"Retinoid acid syndrome (fever, dyspnea, weight gain, pulmonary infiltrates)"},{"rate":"50-80","effect":"Hypertriglyceridemia"},{"rate":"40-60","effect":"Hypercholesterolemia"},{"rate":"20-40","effect":"Headache"},{"rate":"80-90","effect":"Dry skin and mucous membranes"},{"rate":"10-30","effect":"Bone pain"},{"rate":"null","effect":"Teratogenicity (if exposed during pregnancy)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isotretinoin is a highly potent vitamin A derivative that acts as a ligand for retinoid receptors (RAR and RXR), modulating transcription of genes involved in cell differentiation, proliferation, and apoptosis. By promoting terminal differentiation and triggering apoptosis in malignant cells, it reduces tumor burden and prevents relapse. Cipher Pharmaceuticals' formulation (CIP-Isotretinoin) likely represents a novel delivery or dosing approach to the established isotretinoin mechanism.","oneSentence":"CIP-Isotretinoin is a retinoid that binds to nuclear retinoid receptors to regulate gene expression and promote differentiation and apoptosis of abnormal cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:56.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL)"},{"name":"High-risk neuroblastoma (maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT00975143","phase":"PHASE3","title":"Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne","status":"COMPLETED","sponsor":"Cipher Pharmaceuticals Inc.","startDate":"2009-09","conditions":"Severe Nodular Acne","enrollment":925}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CIP-Isotretinoin","genericName":"CIP-Isotretinoin","companyName":"Cipher Pharmaceuticals Inc.","companyId":"cipher-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CIP-Isotretinoin is a retinoid that binds to nuclear retinoid receptors to regulate gene expression and promote differentiation and apoptosis of abnormal cells. Used for Acute promyelocytic leukemia (APL), High-risk neuroblastoma (maintenance therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}